Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cell-to-cell
100%
Cell Therapy
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Cell Transplantation
100%
Hematological Malignancies
40%
Clinical Outcomes
20%
Lymphoid Malignancies
20%
Practice Guidelines
20%
Acute Toxicity
20%
Adoptive Immunotherapy
20%
Clinical Indications
20%
Chronic Toxicity
20%
Alloreactivity
20%
Individualized Approach
20%
Competitive Roles
20%
Genetically Engineered
20%
Graft-versus-tumor Effect
20%
Sustained Remission
20%
Medicine and Dentistry
Cell Transplantation
100%
Cell Therapy
100%
Chimeric Antigen Receptor T-Cell
100%
Hematopoietic Cell
83%
Chimeric Antigen Receptor T-Cell Immunotherapy
66%
Hematologic Malignancy
33%
Immunotherapy
16%
Chronic Toxicity
16%
Alloimmunity
16%
Graft Versus Tumor Effect
16%
Diseases
16%
Lymphoma
16%
Nursing and Health Professions
Cell Therapy
100%
Chimeric Antigen Receptor T-Cell
100%
Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
66%
Hematologic Malignancy
33%
Remission
16%
Practice Guideline
16%
Clinical Outcome
16%
Immunotherapy
16%
Acute Toxicity
16%
Chronic Toxicity
16%
Diseases
16%
Lymphoma
16%
Graft Versus Tumor Effect
16%
Immunology and Microbiology
Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell
100%
Hematopoietic Cell
83%
Chimeric Antigen Receptor T-Cell Therapy
66%
Immunotherapy
16%
Alloimmunity
16%
Graft Versus Tumor Effect
16%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Cell Transplantation
100%
Chimeric Antigen Receptor
100%
Hematopoietic Cell
83%
Alloimmunity
16%